NEGGRAM
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral suspension small molecule approved in 1973 by Sanofi. The specific mechanism of action and therapeutic indications are not publicly detailed in available data. This legacy product represents a mature asset in the small molecule portfolio.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in optimization mode with potential headcount constraints as patent exclusivity erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEGGRAM offers limited career growth potential given the approaching loss of exclusivity and minimal linked job openings (0). This role is best suited for professionals seeking stability on a mature, legacy product rather than launch or growth-stage experience.
Brand ManagerField Sales Representative
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.